| Schedule of basic and diluted net income loss per share |
The
following table sets forth the computation of basic and diluted net income (loss) per share (in thousands, except share and per
share data):
Schedule of basic and diluted net income loss per share
| | |
|
|
|
|
|
| | |
|
|
|
|
|
| |
| | |
Three
Months Ended
June 30, | | |
Six
Months Ended
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator: | |
| | |
| | |
| | |
| |
| Consolidated net income (loss) | |
$ | 452 | | |
$ | (18,711 | ) | |
$ | (5,892 | ) | |
$ | (34,045 | ) |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Denominator for basic net income (loss) per share - weighted-average common stock outstanding | |
| 1,660,586 | | |
| 1,170,087 | | |
| 1,581,554 | | |
| 1,167,550 | |
| Effect of dilutive securities: | |
| | | |
| | | |
| | | |
| | |
| RSUs | |
| 1,123 | | |
| — | | |
| — | | |
| — | |
| Denominator for diluted net income (loss) per share - adjusted weighted-average common stock outstanding | |
| 1,661,709 | | |
| 1,170,087 | | |
| 1,581,554 | | |
| 1,167,550 | |
| Basic net income (loss) per share | |
$ | 0.27 | | |
$ | (15.99 | ) | |
$ | (3.73 | ) | |
$ | (29.16 | ) |
| Diluted net income (loss) per share | |
$ | 0.27 | | |
$ | (15.99 | ) | |
$ | (3.73 | ) | |
$ | (29.16 | ) |
|
|
| Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share |
Potentially
dilutive securities not included in the calculation of diluted net income (loss) per common share because to do so would be anti-dilutive
are as follows (in common stock equivalents):
Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share
| | |
|
|
|
|
|
| |
| | |
As
of June 30, | |
| | |
2026 | | |
2025 | |
| Common stock warrants | |
| 193,581 | | |
| 193,581 | |
| Common stock options | |
| 114,059 | | |
| 118,249 | |
| Restricted stock units | |
| 57,404 | | |
| 52,130 | |
| ESPP shares | |
| 380 | | |
| 1,374 | |
| Total | |
| 365,424 | | |
| 365,334 | |
|
Potentially
dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive
are as follows (in common stock equivalents):
| Schedule of anti-dilutive securities excluded from calculation of diluted net loss per share |
|
|
|
|
|
|
|
| |
December
31, |
|
| |
2025 |
|
|
2024 |
|
| Common
stock warrants |
|
193,581 |
|
|
|
193,581 |
|
| Common
stock options |
|
117,581 |
|
|
|
121,920 |
|
| Restricted
stock units |
|
48,678 |
|
|
|
31,060 |
|
| ESPP
shares |
|
991 |
|
|
|
1,577 |
|
| PPA
Shares |
|
136,923 |
|
|
|
— |
|
| Total |
|
497,754 |
|
|
|
348,138 |
|
|